JDRF, Amylin in diabetes partnership

The Juvenile Diabetes Research Foundation (JDRF) partnered with Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) to investigate the feasibility of a fixed combination of Amylin's Symlin pramlintide and insulin to treat Type I diabetes. Amylin will conduct up to three clinical studies to investigate the optimal Symlin/insulin ratios and to determine whether delivery of a fixed ratio of the two can improve glucose control in Type I diabetics. Both parties are jointly sharing costs of the research program. ...